Woodline Partners LP acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 526,511 shares of the company's stock, valued at approximately $8,656,000. Woodline Partners LP owned about 0.98% of Upstream Bio as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in Upstream Bio during the 4th quarter valued at $25,000. US Bancorp DE purchased a new position in shares of Upstream Bio during the fourth quarter valued at $27,000. Legal & General Group Plc acquired a new position in Upstream Bio during the fourth quarter valued at $28,000. Summit Investment Advisors Inc. purchased a new stake in Upstream Bio in the 4th quarter worth about $30,000. Finally, Tower Research Capital LLC TRC acquired a new stake in Upstream Bio during the 4th quarter worth about $47,000.
Upstream Bio Trading Up 4.3%
NASDAQ:UPB traded up $0.39 on Tuesday, hitting $9.55. 497,107 shares of the company's stock traded hands, compared to its average volume of 328,721. The firm has a 50-day moving average price of $8.05 and a 200-day moving average price of $12.14. Upstream Bio, Inc. has a 1 year low of $5.14 and a 1 year high of $29.46.
Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. As a group, equities research analysts forecast that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
